Literature DB >> 3573536

Glomerular hypertension and injury in desoxycorticosterone-salt rats on antihypertensive therapy.

L D Dworkin, H D Feiner, J Randazzo.   

Abstract

Uninephrectomized male Munich-Wistar rats received either weekly subcutaneous injections of vehicle and water for drinking; injections of desoxycorticosterone (DOC) and 1% saline (SALT) for drinking; or DOC and SALT with hydrochlorthiazide, hydralazine, reserpine and KCl added. All studies were performed six weeks after UNX. At that time, rats receiving DOC and SALT alone were hypertensive and had significantly more proteinuria and morphologic evidence of glomerular injury than rats given vehicle and tap water which were normotensive. Antihypertensive therapy normalized mean arterial pressure in DOC-SALT rats, but failed to prevent proteinuria, mesangial expansion or focal segmental glomerular lesions. Micropuncture studies revealed that glomerular capillary pressure was elevated in both untreated and treated DOC-SALT animals. We conclude that drugs which successfully reduce systemic blood pressure may fail to correct glomerular capillary hypertension in DOC-SALT rats. As persistence of intrarenal hypertension is associated with significant glomerular injury, normalization of glomerular capillary pressure rather than systemic arterial pressure is crucial to the prevention of glomerular injury in this model.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3573536     DOI: 10.1038/ki.1987.57

Source DB:  PubMed          Journal:  Kidney Int        ISSN: 0085-2538            Impact factor:   10.612


  10 in total

Review 1.  Renal autoregulation in health and disease.

Authors:  Mattias Carlström; Christopher S Wilcox; William J Arendshorst
Journal:  Physiol Rev       Date:  2015-04       Impact factor: 37.312

2.  Synergistic Interaction of Hypertension and Diabetes in Promoting Kidney Injury and the Role of Endoplasmic Reticulum Stress.

Authors:  Zhen Wang; Jussara M do Carmo; Nicola Aberdein; Xinchun Zhou; Jan M Williams; Alexandre A da Silva; John E Hall
Journal:  Hypertension       Date:  2017-03-27       Impact factor: 10.190

Review 3.  Impact of calcium entry blockers on glomerular injury in experimental hypertension.

Authors:  L D Dworkin
Journal:  Cardiovasc Drugs Ther       Date:  1990-10       Impact factor: 3.727

4.  Intermedin ameliorates vascular and renal injury by inhibition of oxidative stress.

Authors:  Makoto Hagiwara; Grant Bledsoe; Zhi-Rong Yang; Robert S Smith; Lee Chao; Julie Chao
Journal:  Am J Physiol Renal Physiol       Date:  2008-10-01

Review 5.  Acute and chronic effects of angiotensin converting enzyme inhibitors on the essential hypertensive kidney.

Authors:  G P Reams; J H Bauer
Journal:  Cardiovasc Drugs Ther       Date:  1990-02       Impact factor: 3.727

Review 6.  Do calcium channel blockers have renal protective effects?

Authors:  G P Reams
Journal:  Drugs Aging       Date:  1994-10       Impact factor: 3.923

7.  Podocyte damage is a critical step in the development of glomerulosclerosis in the uninephrectomised-desoxycorticosterone hypertensive rat.

Authors:  M Kretzler; I Koeppen-Hagemann; W Kriz
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

8.  Role of endogenous CYP450 metabolites of arachidonic acid in maintaining the glomerular protein permeability barrier.

Authors:  Jan Michael Williams; Mukut Sharma; Siddam Anjaiahh; John R Falck; Richard J Roman
Journal:  Am J Physiol Renal Physiol       Date:  2007-05-16

9.  The Nephrotoxin Puromycin Aminonucleoside Induces Injury in Kidney Organoids Differentiated from Induced Pluripotent Stem Cells.

Authors:  Lisa Nguyen; Wasco Wruck; Lars Erichsen; Nina Graffmann; James Adjaye
Journal:  Cells       Date:  2022-02-11       Impact factor: 7.666

10.  Podocyte injury in diabetic nephropathy: implications of angiotensin II-dependent activation of TRPC channels.

Authors:  Daria V Ilatovskaya; Vladislav Levchenko; Andrea Lowing; Leonid S Shuyskiy; Oleg Palygin; Alexander Staruschenko
Journal:  Sci Rep       Date:  2015-12-10       Impact factor: 4.379

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.